Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04291105 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

StatusActive, Not Recruiting
PhasePhase 2
Started2020-04-24
View on ClinicalTrials.gov ↗
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)

Amendment record

Amended 26 times since 2020-02-28; most recent filed 2026-07-06. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-07-06
Amendment Recruiting→Active, Not Recruiting Study Identification, Study Status, Oversight, Study Description, Arms and Interventions, Contacts/Locations v26
2025-03-25
Amendment Study Status, Oversight, Contacts/Locations v25
2024-09-30
Amendment Study Status, Contacts/Locations v24
2024-07-23
Amendment Study Status, Eligibility, Contacts/Locations v23
2024-04-22
Amendment Study Status, Arms and Interventions, Contacts/Locations v22
2023-10-31
Amendment Study Status, Contacts/Locations v21
2023-06-26
Amendment Study Status, Contacts/Locations v20
2023-03-13
Amendment Study Identification, Study Status, Study Description, Conditions, Study Design, Arms and Interventions, Eligibility, Contacts/Locations v19
2022-04-21
Amendment Study Status, Arms and Interventions, Eligibility, Contacts/Locations v18
2022-01-06
Amendment Study Status, Study Description, Conditions, Study Design, Arms and Interventions, Eligibility, Contacts/Locations v17
2021-07-06
Amendment Study Status, Contacts/Locations v16
2021-05-28
Amendment Study Status, Contacts/Locations v15
2021-03-22
Amendment Study Status, Contacts/Locations v14
2021-03-02
Amendment Study Status, Eligibility, Contacts/Locations v13
2021-01-05
Amendment Study Status, Contacts/Locations v12
2020-10-22
Amendment Study Status, Contacts/Locations v11
2020-10-09
Amendment Study Status, Contacts/Locations v10
2020-10-06
Amendment Study Status, Contacts/Locations v9
2020-09-18
Amendment Study Status, Contacts/Locations v8
2020-09-15
Amendment Study Status, Contacts/Locations v7
2020-09-11
Amendment Study Status, Contacts/Locations v6
2020-09-11
Amendment Study Status, Contacts/Locations v5
2020-06-24
Amendment Study Status, Contacts/Locations v4
2020-05-21
Amendment Study Status, Contacts/Locations v3
2020-05-08
Amendment Not Yet Recruiting→Recruiting Study Status, Study Description, Arms and Interventions, Eligibility, Contacts/Locations v2
2020-03-03
Amendment Study Identification, Study Status, Study Description, Contacts/Locations v1
2020-02-28
Original filing
Trial Details
NCT Number NCT04291105
Lead Sponsor Vyriad, Inc.
Collaborators: Regeneron Pharmaceuticals
Conditions Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Enrollment 87 participants
Start Date 2020-04-24
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-08